Back

Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.

Ribupatide

PipelinePhase 3PeptideInvestigational

Sponsor:: Kailera
Active US trials:: 4
Earliest primary completion:: May 1, 2027

👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

Similar Products

WEGOVY

Zepbound

FOUNDAYO

Contrave Extended-Release

Synopsis

Generated with AlphaAI

Product:

Ribupatide

Category:

Indication:

Mechanism:

Safety:

Dosing:

Patient:

Reviews:

No reviews yet

Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (4)

NCT	Phase	Status	Sponsor	Primary Completion
NCT07284875	Phase 3	ACTIVE_NOT_RECRUITING	Kailera	Feb 1, 2028
NCT07458269	Phase 2	ACTIVE_NOT_RECRUITING	Kailera	May 1, 2027

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Ribupatide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers